Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MBX BiosciencesMBX -3.25%12 3-1 Month Momentum % is 30.76% as of Jul. 23, 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,388 Biotechnology companies, MBX Biosciences ranks better than 92.44% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), MBX Biosciences's 3-1 Month Momentum % is 30.76%.
The industry rank for MBX Biosciences's 3-1 Month Momentum % or its related term are showing as below:
MBX's 3-1 Month Momentum % is ranked better than 92.44% of 1388
companies
in the Biotechnology industry
Industry Median: -12.625
vs MBX: 30.76
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
MBX Biosciences 3-1 Month Momentum % Related Terms
MBX vs SLS, TRVI, BHVN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, MBX Biosciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MBX Biosciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MBX Biosciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where MBX Biosciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBX Biosciences (MBX) has a 3-1 Month Momentum % of 30.76% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MBX Biosciences and its competitors. According to the industry distribution chart, MBX Biosciences ranks #105 out of 1388 companies in the Biotechnology industry, placing it in the top 7.6%.
Is MBX Biosciences' 3-1 Month Momentum % too high?
MBX Biosciences' current 3-1 Month Momentum % is 30.76%. Based on the distribution chart, MBX Biosciences ranks #105 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' 3-1 Month Momentum % compare to SLS and TRVI?
According to the Biotechnology industry distribution chart, MBX Biosciences ranks #105 out of 1388 companies for 3-1 Month Momentum %. This places MBX Biosciences in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current 3-1 Month Momentum % is 30.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current 3-1 Month Momentum % of 30.76%. The current 3-1 Month Momentum % is 30.76%. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For MBX Biosciences (MBX), the current 3-1 Month Momentum % is 30.76% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score
Get the complete analysis for MBX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBX has been successfully added to your 
